Predict your next investment

Corporation
HEALTHCARE | Biotechnology
ginkgobioworks.com

See what CB Insights has to offer

Founded Year

2009

Stage

PIPE | IPO

Total Raised

$796.25M

Market Cap

26.95B

Stock Price

13.14

About Ginkgo BioWorks

Ginkgo Bioworks (NYSE: DNA) designs and prints DNA. The company can design the living code to build custom microorganisms with lower environmental impact and waste for customers in a wide range of industries including pharmaceuticals, consumer goods, consumer electronics, cosmetics, nutrition, food, agriculture, medicine and more.

Ginkgo BioWorks Headquarter Location

27 Drydock Avenue 8th Floor

Boston, Massachusetts, 02210,

United States

877-422-5362

Latest Ginkgo BioWorks News

Ginkgo Bioworks Investor Alert

Oct 22, 2021

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ginkgo Bioworks To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - October 21, 2021) -  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ginkgo Bioworks Holdings, Inc. ("Ginkgo Bioworks" or the "Company") (NYSE: DNA). If you suffered losses exceeding $50,000 investing in Ginkgo Bioworks stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: http://www.faruqilaw.com/DNA . There is no cost or obligation to you. Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Delaware, Pennsylvania, California and Georgia. On October 6, 2021, Scorpion Capital published a report about Ginkgo alleging that it is a "colossal scam." It describes the Company's business model as a "shell game," and that the company is highly dependent on related party transaction revenues. The report also calls the company a "Frankenstein mash-up of the worst frauds of the last 20 years." On this news, the Company's share price fell as much as 20%, during intraday trading on October 6, 2021, thereby injuring investors. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/100524 Sign up for Alerts Sign up to receive news releases by email for Faruqi & Faruqi LLP or all companies belonging to the Banking/Financial Services industry.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Ginkgo BioWorks

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Ginkgo BioWorks in 16 CB Insights research briefs, most recently on Sep 30, 2021.

Expert Collections containing Ginkgo BioWorks

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ginkgo BioWorks is included in 6 Expert Collections, including Genomics.

G

Genomics

823 items

Companies involved in the capture, sequencing, and/or analysis of genetic data

S

Synthetic Biology

617 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

F

Feeding the Future

35 items

The startups highlighted in the CB Insights 2017 Feeding the Future report, focused on transforming the ways our food is grown, stored, shipped and sold.

F

Future of Pharma R&D

62 items

I

Industrial SynBio

449 items

Synthetic biology focused on replacing industrial and commercial materials.

Ginkgo BioWorks Patents

Ginkgo BioWorks has filed 24 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • Genetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/23/2019

6/22/2021

Biotechnology, Molecular biology, Cell biology, Transcription factors, EC 4.2.1

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/23/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/22/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Biotechnology, Molecular biology, Cell biology, Transcription factors, EC 4.2.1

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Ginkgo BioWorks Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ginkgo BioWorks Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.